Telesis Bio (NASDAQ:TBIO) Trading Down 6.8%

Shares of Telesis Bio, Inc. (NASDAQ:TBIO) traded down 6.8% during mid-day trading on Friday . The company traded as low as $0.32 and last traded at $0.33. 145,341 shares changed hands during trading, a decline of 75% from the average session volume of 579,324 shares. The stock had previously closed at $0.35.

Telesis Bio Stock Performance

The company has a market capitalization of $9.93 million, a price-to-earnings ratio of -0.20 and a beta of 1.93. The company has a 50 day moving average price of $0.45 and a 200 day moving average price of $0.46. The company has a debt-to-equity ratio of 22.76, a quick ratio of 3.22 and a current ratio of 3.71.

Telesis Bio (NASDAQ:TBIO) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. The business had revenue of $6.98 million for the quarter. Telesis Bio had a negative return on equity of 176.47% and a negative net margin of 173.78%.

Telesis Bio Company Profile

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits which contains the necessary building blocks and reagents, including proprietary gibson assembly branded reagents, for specific synthetic biology workflow applications.